Lumoxiti

Active Ingredient(s): Moxetumomab Pasudotox-tdfk
FDA Approved: * September 13, 2018
Pharm Company: * ASTRAZENECA AB
Category: Cancer

Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.[2][3][4] Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL.[4] The drug consist... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Lumoxiti 1 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution

NDC: 0310-4700

Labeler:

Astrazeneca Pharmaceuticals Lp